European stocks are expected to open in mixed territory as investors assess a confused picture of where the Iran war and peace talks are headed.
VCI Global (NASDAQ: VCIG - Get Free Report) and Rentokil Initial (NYSE: RTO - Get Free Report) are both business services companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk. Analyst Ratings This is a summary of
Rentokil Initial plc (RTO) shows stabilization in 2025, with North America organic growth improving and streamlining efforts beginning to yield results. RTO's recurring significant earnings adjustments and complex reporting continue to obscure true underlying performance, justifying a valuation discount. Leverage remains elevated at 7.5x free cash flow, and although free cash flow covers the dividend, the balance sheet is not robust.
Rentokil (RTO) offers a more attractive valuation and diversified growth profile than peer Rollins, trading at a significant discount despite similar growth drivers. RTO reported FY'25 revenues of $6.91B (+3.8% YoY), with organic growth, margin expansion, and strong free cash flow supporting deleveraging and investment-grade credit ratings. Industry tailwinds, operational efficiencies, and a robust M&A pipeline underpin expectations for mid-to-high single-digit EPS growth and margin improvement toward 20%+ by 2027.
Rentokil Initial plc (RTO) Q4 2025 Earnings Call Transcript
Shares in Rentokil Initial PLC jumped 9.2% to 464.6p on Thursday as the pest control giant reported full-year results that met or beat market expectations, helped by improving momentum in North America. Revenue from continuing operations rose 4.4% to $6.9 billion and adjusted operating profit climbed 5.4% to $1.1 billion, both in line with the $6.9 billion City analyst consensus.
The pest-control, hygiene and workwear-services provider's revenue climbed 2.6% organically in 2025.
Roquefort Therapeutics PLC (LSE:ROQ),a biotech company currently valued at less than £1.5 million, is set to be transformed into a clinical-stage oncology business after announcing the £32 million acquisition of an exclusive worldwide licence to a promising cancer drug alongside a £8.5 million fundraise. The company is acquiring the rights to AO-252, an orally administered small molecule drug targeting TACC3, a protein that is over-expressed in many aggressive tumours, from Coiled Therapeutics, a spin-out of A2A Pharma Pharmaceuticals.
Rentokil Initial PLC (LSE:RTO) has been downgraded from 'buy' to 'hold' at Deutsche Bank, with the target price cut from 505p to 465p. Analysts frame the thesis carefully.
Rentokil Initial (RTO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here is how Rentokil Initial PLC (RTO) and SGS SA (SGSOY) have performed compared to their sector so far this year.
Investors interested in Business - Services stocks are likely familiar with Rentokil Initial PLC (RTO) and Thomson Reuters (TRI). But which of these two stocks offers value investors a better bang for their buck right now?